- Home
- MED vs IPHA Comparison
MED vs IPHA Comparison
Compare MED & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MED | IPHA |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MED | IPHA |
|---|---|---|
| Price | $10.95 | $1.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.50 | $5.00 |
| AVG Volume (30 Days) | ★ 300.8K | 26.4K |
| Earning Date | 02-17-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $429,695,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | $453.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.10 | $1.60 |
| 52 Week High | $17.82 | $2.63 |
Technical Indicators
Market Signals| Indicator | MED | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 47.64 |
| Support Level | $10.44 | $1.70 |
| Resistance Level | $11.37 | $1.85 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 36.96 | 51.61 |
Price Performance
Historical ComparisonAbout MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.